
IPG Photonics (IPGP) Stock Forecast & Price Target
IPG Photonics (IPGP) Analyst Ratings
Bulls say
IPG Photonics is benefiting from clear fundamental improvement, as Q3 revenue rose 14.6% year over year to $287.5MM, adjusted EBITDA increased 39% to $51.5MM, and adjusted gross margin held at 40.7%, showing stronger operating leverage despite a challenging backdrop. Growth was broad-based across Industrial Solutions and Advanced Solutions, while North America and China each grew 33%, and a book-to-bill around 1.0 suggests demand remains healthy. The outlook is further supported by $884MM of net cash/investments, over $1B of stock repurchases over the last three years, and the pending Lumibird Medical acquisition, which should expand IPG’s medical exposure and support higher-margin, more durable growth.
Bears say
IPG Photonics is viewed negatively because its industrial business is highly cyclical and exposed to a weakening global macro industrial economy, making demand vulnerable if manufacturing conditions deteriorate. Intensifying competition, inflationary pressures, and possible tariffs or adverse trade policies further threaten revenue and earnings, while first-quarter cash generation turned negative with cash from operations of $(5)MM versus $13MM in the prior-year period and free cash flow of $(22)MM after $16MM of capital expenditures. The absence of stock repurchases during the quarter, combined with management’s note that annual bonus payments weighed on cash flow, reinforces concerns about weaker near-term financial flexibility.
This aggregate rating is based on analysts' research of IPG Photonics and is not a guaranteed prediction by Public.com or investment advice.
IPG Photonics (IPGP) Analyst Forecast & Price Prediction
Start investing in IPG Photonics (IPGP)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About IPG Photonics (IPGP) Forecast
IPG Photonics (IPGP) Analyst Forecast & Price Prediction
Start investing in IPG Photonics (IPGP)
Order type
Buy in
Order amount
Est. shares
0 shares